Alvotech disclosed its fourth‑quarter and full‑year 2025 financial results, reporting total revenue of $173 million for Q4 and $593 million for the year, both up 13 % and 21 % respectively from the same periods in 2024.
The company’s Q4 revenue of $173 million surpassed analysts’ consensus of $161 million, driven by strong licensing and product sales. Year‑over‑year growth was supported by a 13 % increase in product revenue, while the prior quarter’s $492 million revenue in Q4 2024 provides context for the acceleration.
Alvotech’s GAAP earnings per share for Q4 were $0.03, beating the consensus estimate of a $0.08 loss. Non‑GAAP EPS, however, was a loss of $0.37, reflecting one‑time charges and the impact of a negative product margin of 37 % caused by timing of orders and planned facility upgrades.
Gross margin for the quarter stood at 66 %, and adjusted EBITDA reached $69 million, a 40 % margin. The negative product margin was attributed to lower throughput during the second half of 2025, as the company upgraded its manufacturing facilities.
Management reaffirmed its 2026 guidance, projecting revenue of $650–$700 million and adjusted EBITDA of $180–$220 million. The lower end of the revenue range assumes no U.S. product launches in 2026, reflecting ongoing regulatory uncertainty.
Chief Executive Officer Róbert Wessman highlighted the expansion of Alvotech’s biosimilars platform, the addition of new commercial partners, and the company’s pipeline of 30 biosimilars in development. Chief Financial Officer Linda Jónsdóttir noted that the quarter’s performance “landed within our guidance,” driven primarily by licensing revenues, and that year‑end cash stood at $172 million after financing activities.
Investors focused on the EPS miss and regulatory hurdles, tempering enthusiasm for the revenue beat. The company’s recent FDA Complete Response Letter for AVT05 and ongoing U.S. regulatory setbacks were cited as key concerns.
Alvotech’s tailwinds include multiple biosimilar approvals in the U.K., EEA, and Japan, as well as strategic partnerships with Sandoz and other global players. These developments support the company’s long‑term growth trajectory.
The company’s guidance and financial performance suggest confidence in its biosimilar platform, but the regulatory challenges and negative product margin highlight short‑term operational pressures that investors will monitor closely.
The overall outlook remains positive, with Alvotech positioned to capture market share in key regions while navigating regulatory and operational headwinds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.